Neurocrine Biosciences, Inc. will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle ...

Genesys®, a global cloud leader in AI-Powered Experience Orchestration, and TeKnowledge, a global company providing expert technology services for AI, Customer Experience and Cybersecurity, today ...

In addition, we are pleased to confirm a promising Nav1.2/Nav1.6 sodium channel inhibitor discovered in Xenon labs has progressed into a Phase 1 study as part of our collaboration with Neurocrine ...

Since the 1960s, people have been searching for the mythical creature known as Bigfoot. Most cryptozoologists would place him ...

As part of Xenon's ongoing collaboration with Neurocrine Biosciences to develop treatments ... webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its fourth quarter and ...

Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00.

Children ages two to eight years across 11 Pacific jurisdictions (Alaska, American Samoa, Commonwealth of the Northern ...

Pacific Biosciences of California, Inc. has a 52-week low of $1.16 and a 52-week high of $5.01. The company has a market cap of $366.98 million, a price-to-earnings ratio of -0.82 and a beta of 1.92.

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find ...